Brivaracetam efficacy and tolerability in clinical practice : A UK-based retrospective multicenter service evaluation

Adewusi, J. and Burness, C. and Ellawela, S. and Emsley, H. and Hughes, R. and Lawthom, C. and Maguire, M. and McLean, B. and Mohanraj, R. and Oto, M. and Singhal, S. and Reuber, M. (2020) Brivaracetam efficacy and tolerability in clinical practice : A UK-based retrospective multicenter service evaluation. Epilepsy and Behavior, 106: 106967. ISSN 1525-5050

Full text not available from this repository.


Purpose: This multicenter service evaluation explores the efficacy and tolerability of brivaracetam (BRV) in an unselected, consecutive population in ‘real-life’ clinical settings. Method: We retrospectively collected data from patient records at 11 UK hospitals and epilepsy centers. Consecutive patients prescribed BRV with at least 3 months of follow-up (FU) were included. Apart from reporting effectiveness and tolerability of BRV across the whole cohort, we compared treatment outcomes depending on previous levetiracetam use (LEV + versus LEV −), comorbid learning disability (LD + versus LD −), and epilepsy syndrome (focal versus generalized epilepsy). Results: Two hundred and ninety patients (46% male, median age: 38 years, range: 15 to 77) with ≥ 3 months of FU were included. The median duration of BRV exposure was 12 months (range: 1 day to 72 months). Overall BRV retention was 71.1%. While 56.1% of patients improved in terms of seizure frequency category (daily, weekly, monthly, yearly seizures), 23.1% did not improve on this measure and 20.8% deteriorated. In terms of seizure frequency, 21% of patients experienced a ≥ 50% reduction, with 7.0% of all patients becoming seizure-free. Treatment-emergent adverse events (AEs) were reported by 107 (36.9%) patients, but there were no serious AEs. The commonest AEs were sedation/fatigue (18.3%), mood changes (9.0%), and irritability/aggression (4.8%). There were no significant differences in drug retention, seizure frequency outcomes, or AEs between the LEV + and LEV − subgroups, or between patients with generalized or focal epilepsies. Although 15.5% of patients in the LD + group achieved a ≥ 50% reduction, this rate was lower than in the LD − group. Conclusions: This ‘real-life’ evaluation suggests that reductions in seizure frequency can be achieved with BRV in patients with highly refractory epilepsy. Brivaracetam may be a useful treatment option in patients who have previously failed to respond to or tolerate LEV, those with LD, or (off-label) those with generalized epilepsies.

Item Type:
Journal Article
Journal or Publication Title:
Epilepsy and Behavior
Uncontrolled Keywords:
?? brivaracetamepilepsylearning disabilitylevetiracetamseizure controltolerabilityneurologyclinical neurologybehavioral neuroscience ??
ID Code:
Deposited By:
Deposited On:
27 Apr 2021 12:50
Last Modified:
15 Jul 2024 20:57